Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Tables)

v2.4.0.8
Composition of Certain Financial Statement Captions (Tables)
6 Months Ended
Jun. 30, 2014
Compositions of Certain Financial Statement Captions [Abstract]  
Composition of certain financial statement captions
(In thousands)
June 30,
2014
 
December 31,
2013
Accounts receivable, net
 
 
 
Accounts receivable
$
24,660

 
$
21,652

Less: allowance for doubtful accounts
(1,547
)
 
(1,885
)
 
$
23,113

 
$
19,767

Inventories, net
 
 
 
Finished products
$
12,455

 
$
13,374

Work in-process
1,510

 
1,350

Raw materials
4,948

 
4,132

Less: inventory reserve
(579
)
 
(777
)
 
$
18,334

 
$
18,079

Prepaid expenses and other current assets
 
 
 
Prepaid supplies
$
1,910

 
$
945

Prepaid insurance
1,113

 
892

Pharmsynthez notes receivable

 
6,151

Other receivables
619

 
1,985

Taxes recoverable
1,298

 
3,458

Other
2,613

 
5,653

 
$
7,553

 
$
19,084

Intangible assets, net:
 
 
 
Technologies
$
53,012

 
$
51,660

Customer relationships
22,511

 
22,725

Product registrations
9,687

 
9,692

Tradenames
3,615

 
3,669

Covenants not to compete
8,669

 
8,671

Other
1,190

 
2,519

Less:  accumulated amortization
(29,625
)
 
(24,403
)
 
$
69,059

 
$
74,533

Accrued expenses:
 
 
 
Taxes payable
$
406

 
$
702

Deferred revenue
6,393

 
7,639

Clinical trials
2,616

 
3,342

Professional fees
1,320

 
402

Employee benefits
5,405

 
4,399

Deferred acquisition payments, net of discount

 
5,465

Contingent consideration
24,618

 
28,047

Other
14,206

 
15,878

 
$
54,964

 
$
65,874

 
 
 
 
(In thousands)
June 30,
2014
 
December 31,
2013
Other long-term liabilities:
 
 
 
Contingent consideration – OPKO Renal
$
37,141

 
$
34,401

Contingent consideration – OPKO Spain
299

 
504

Contingent consideration – OPKO Diagnostics
10,642

 
8,340

Contingent consideration – CURNA
214

 
316

Mortgages and other debts payable
2,948

 
3,270

Deferred tax liabilities
165,226

 
166,435

Other, including deferred revenue
2,020

 
1,509

 
$
218,490

 
$
214,775

Schedule of goodwill
The following table summarizes the changes in Goodwill during the six months ended June 30, 2014.
 
2014
(In thousands)
Balance at January 1
 
Acquisitions
 
Foreign exchange, other
 
Balance at June 30
Pharmaceuticals
 
 
 
 
 
 
 
CURNA
$
4,827

 
$

 
$

 
$
4,827

Exakta-OPKO
113

 

 

 
113

OPKO Chile
6,102

 

 
(310
)
 
5,792

OPKO Spain
9,075

 

 
(79
)
 
8,996

FineTech
11,698

 

 

 
11,698

SciVac
1,740

 

 
17

 
1,757

OPKO Renal
2,069

 

 

 
2,069

OPKO Biologics
139,784

 

 

 
139,784

Diagnostics
 
 
 
 
 
 
 
Claros
17,977

 

 

 
17,977

OPKO Lab
32,988

 

 

 
32,988

 
$
226,373

 
$

 
$
(372
)
 
$
226,001